1: Park YH, Chung CU, Park BM, Park MR, Park DI, Moon JY, Park HS, Kim JH, Jung SS, Kim JO, Kim SY, Lee JE. Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs. Can Respir J. 2016;2016:3576201. doi: 10.1155/2016/3576201. Epub 2016 Nov 27. 2: Oh IJ, Kim KS, Park CK, Kim YC, Lee KH, Jeong JH, Kim SY, Lee JE, Shin KC, Jang TW, Lee HK, Lee KY, Lee SY. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. BMC Cancer. 2016 Aug 26;16:690. doi: 10.1186/s12885-016-2741-z. 3: Mulholland K, Wu C. Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone. J Chem Inf Model. 2016 Sep 26;56(9):1872-83. doi: 10.1021/acs.jcim.6b00317. Epub 2016 Sep 1. doi: 10.1002/ardp.201500045. Epub 2015 Apr 27. doi: 10.1002/med.21342. Epub 2015 Mar 21. Review.
合成参考文献
参考文献:10.1007/s00280-011-1664-2 摘要:La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, Zamboni WC. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol. 2012 Jan;69(1):43–50. doi: 10.1007/s00280-011-1664-2.